Entera Bio (ENTX) vs Scribe Therapeutics (SCTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Entera Bio is the larger company by market cap ($462.4 million vs $400.8 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENTX | SCTX |
|---|---|---|
| Share price | $2.66 | $21.17 |
| Market cap | $462.40M | $400.78M |
| 1-day change | +6.40% | +10.09% |
| YTD return | +37.11% | — |
| 1-year return | +5.98% | — |
| 5-year return | -44.69% | — |
| EPS (TTM) | $-0.36 | $-3.84 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.20 | $39.60 |
| 52-week low | $0.91 | $13.50 |
| Distance from 52-week high | -36.67% | -46.54% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +266.54% | +169.25% |
| Average volume | 1.82M | 357.40K |
| Shares outstanding | 173.83M | 18.93M |
| Employees | 20 | 82 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Entera Bio
ENTX stock →Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 20 employees
About Scribe Therapeutics
SCTX stock →Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 82 employees
ENTX vs SCTX FAQ
Which is bigger, Entera Bio or Scribe Therapeutics?
Entera Bio (ENTX) is larger, with a market capitalization of $462.40M compared with $400.78M for Scribe Therapeutics (SCTX).
Are Entera Bio and Scribe Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.